Swedbank AB Grows Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Swedbank AB lifted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 44.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,195 shares of the medical instruments supplier's stock after purchasing an additional 2,220 shares during the quarter. Swedbank AB's holdings in West Pharmaceutical Services were worth $2,160,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Findlay Park Partners LLP grew its stake in shares of West Pharmaceutical Services by 30.6% during the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier's stock worth $236,281,000 after purchasing an additional 139,800 shares during the period. Kayne Anderson Rudnick Investment Management LLC grew its stake in West Pharmaceutical Services by 6.8% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 593,692 shares of the medical instruments supplier's stock valued at $195,556,000 after acquiring an additional 37,702 shares during the period. ProShare Advisors LLC grew its stake in West Pharmaceutical Services by 13.9% in the 1st quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier's stock valued at $198,117,000 after acquiring an additional 61,247 shares during the period. Sei Investments Co. grew its stake in West Pharmaceutical Services by 12.7% in the 2nd quarter. Sei Investments Co. now owns 401,026 shares of the medical instruments supplier's stock valued at $132,095,000 after acquiring an additional 45,208 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in West Pharmaceutical Services by 9.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 301,339 shares of the medical instruments supplier's stock valued at $99,258,000 after acquiring an additional 26,947 shares during the period. Institutional investors and hedge funds own 93.90% of the company's stock.

Insider Buying and Selling at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company's stock, valued at approximately $443,400. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.53% of the stock is currently owned by insiders.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $293.32 on Friday. The company's fifty day moving average price is $299.96 and its 200 day moving average price is $325.39. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $413.70. The stock has a market capitalization of $21.37 billion, a P/E ratio of 38.70, a P/E/G ratio of 10.53 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The company had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. During the same period in the prior year, the business posted $2.11 EPS. West Pharmaceutical Services's revenue was down 6.9% compared to the same quarter last year. As a group, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.